IDEXX vs. DHR vs. TMO: Earnings Preview Ahead of Q4 Reports
Key Takeaways
-
IDEXX Laboratories (IDXX) reports Q4 2025 earnings on February 2, 2026, with analysts expecting continued strength in recurring revenue from companion animal diagnostics.
-
Danaher (DHR) reports on January 28, while Thermo Fisher Scientific (TMO) follows in early February, with both facing low-single-digit core growth expectations across life sciences and diagnostics.
-
IDEXX’s focused veterinary diagnostics model delivers higher margins than DHR and TMO’s diversified portfolios, though all three face pressures from U.S. visit trends and constrained research funding.
-
Each company exceeded expectations in Q3: IDEXX posted $1.105 billion in revenue (+13% YoY), DHR $6.1 billion (+4.5% YoY), and TMO $11.12 billion (+5% YoY).
-
Consensus Q4 EPS estimates are approximately $2.93 for IDEXX, $2.15 for Danaher, and $6.45 for Thermo Fisher, with 2026 guidance a key catalyst.
-
Investor sentiment currently favors IDEXX’s pet-health exposure over peers’ heavier reliance on biotech spending.
Earnings Context and Why This Comparison Matters
IDEXX Laboratories’ upcoming Q4 report underscores its leadership in veterinary diagnostics, a resilient $50+ billion market growing an estimated 7–10% annually as pet ownership and spending rise globally. Comparing IDEXX with Danaher and Thermo Fisher—two diversified leaders in human diagnostics and life sciences—highlights a key trade-off: IDEXX’s high-margin, recurring revenue base versus the scale and breadth, but greater cyclicality, of its peers.
All three delivered solid Q3 results, reinforcing sector durability. However, IDEXX’s accelerating international growth and steady innovation pipeline, including new analyzer platforms, position it as a potential standout as investors seek defensive growth amid delayed funding cycles and policy uncertainty.
IDEXX Laboratories (IDXX): Earnings Focus
Analysts expect Q4 revenue of roughly $1.07 billion and EPS near $2.93, supported by 7–10% organic growth in Companion Animal Group diagnostics. Growth drivers include recurring consumables revenue, premium instrument placements, and net pricing gains.
Key indicators to watch include trends in U.S. clinical visits, where recent declines have begun to ease, international performance, which continues to deliver double-digit growth, and adoption of newer offerings such as Cancer Dx and the inVue Dx analyzer. Historically, IDEXX has exceeded expectations by 6–9% on average, with shares often responding positively to upside surprises. Management’s 2026 outlook is likely to emphasize mid-to-high single-digit organic growth supported by continued innovation.
Danaher (DHR): Earnings Focus
Danaher reports Q4 results on January 28, with consensus estimates calling for approximately $6.8 billion in revenue and EPS of $2.15. This follows Q3 results of $6.1 billion in revenue and $1.89 in adjusted EPS, reflecting about 3% core growth.
Bioprocessing consumables remain Danaher’s strongest segment, while Diagnostics has been pressured by pricing reforms in China. Management has reaffirmed full-year EPS guidance of $7.70–$7.80 and continues to target productivity gains of roughly $250 million, supporting margins near 28%. While shares have lagged year to date due to life-sciences softness, Danaher’s operating discipline remains a long-term positive.
Thermo Fisher Scientific (TMO): Earnings Focus
Thermo Fisher is expected to report Q4 earnings in early February, with analysts projecting $11.9–12.0 billion in revenue and EPS around $6.45. In Q3, the company posted $11.12 billion in revenue with 3% organic growth and adjusted EPS of $5.79, alongside a 100-basis-point margin expansion to 23.3%.
Strength in pharma and biotech customers has helped offset weaker academic and government spending. Thermo recently raised full-year revenue guidance to $44.1–44.5 billion and EPS to $22.60–$22.86, underscoring its scale-driven resilience. Still, slower biopharma funding growth may cap upside relative to IDEXX’s veterinary tailwinds.
Head-to-Head Comparison
-
Growth: IDEXX leads with double-digit organic growth, while Danaher and Thermo deliver low-single-digit gains.
-
Valuation: IDEXX trades at a premium multiple reflecting its higher growth and margins; DHR and TMO offer more modest valuations tied to diversified exposure.
-
Margins and Stability: IDEXX’s “razor-and-blade” model supports superior margins, while DHR and TMO benefit from scale and diversified cash flows.
-
Risk Profile: IDEXX is less exposed to biotech funding volatility, though U.S. visit trends remain a risk. DHR and TMO face greater sensitivity to policy changes and research spending cycles.
AI-Based Market View
Tickeron AI Perspective
According to Tickeron’s AI models, IDEXX currently holds the highest probability of outperformance over the next 6–12 months, driven by strong earnings momentum, innovation-led growth, and attractive margins within a stable veterinary diagnostics market. Confirmation will hinge on Q4 results and management’s 2026 guidance, particularly around visit trends and international expansion.
Disclaimers and Limitations
Contributor
IDXX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for IDXX turned positive on September 22, 2026. Looking at past instances where IDXX's MACD turned positive, the stock continued to rise in 28 of 42 cases over the following month. The odds of a continued upward trend are 67%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IDXX's RSI Oscillator exited the oversold zone, 21 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 64%.
Following a +1.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where IDXX advanced for three days, in 178 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 59 cases where IDXX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 66%.
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IDXX as a result. In 61 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 65%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDXX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
IDXX broke above its upper Bollinger Band on September 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IDXX entered a downward trend on September 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating fairly steady price growth. IDXX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (25.840) is normal, around the industry mean (72.578). P/E Ratio (37.179) is within average values for comparable stocks, (146.993). Projected Growth (PEG Ratio) (2.894) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.001) among similar stocks. P/S Ratio (9.042) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 75 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IDXX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of animal health products
Industry MedicalSpecialties
Advertisement